Inhibikase Therapeutics (IKT) Misses Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Join SI Premium – FREE
Inhibikase Therapeutics (NASDAQ: IKT) reported Q2 EPS of ($0.11).
For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
